A randomized double-blind placebo-controlled 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected sq

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Resected Squamous Cell Carcinoma Of The Head And Neck
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) You have been diagnosed with squamous cell carcinoma through a tissue sample examination and the cancer is located in one of the following areas: the mouth, back of the mouth and throat, lower part of the throat, or voice box.
    2. 2) You do not have any remaining cancer as confirmed by CT/MRI imaging and have a high chance of the cancer returning based on 1 or 2 of the following criteria, which are confirmed by local examination of the cancerous tissue: A. The cancer has spread beyond the lining of the lymph nodes (extra-capsular extension) B. The surgical margins have cancerous cells (referred to as R1 or close margin = 1 mm).
    3. 3) You must be in good enough health after surgery to receive radiotherapy.

You may not be eligible for this study if the following are true:

    1. 1) The cancer started in one of these areas: the nasopharynx, paranasal sinuses, nasal cavity, salivary gland, thyroid gland, parathyroid gland, skin, or it is not known where it started.
    2. 2) You had HIV or an active infection with HBV or HCV. If unknown history of HIV, testing will be conducted.
    3. 3) You have a stomach disorder that makes it hard for your body to absorb nutrients or you had a stomach surgery in the last year that might make it difficult for you to take medicine by mouth.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.